Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 46
HOS-109546 · Präparat HOS-093201
Other benzodiazepines Although not studied, voriconazole (including but not limited to: is likely to increase the plasma triazolam, alprazolam) concentrations of other benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect. Cardiovascular agents Ivabradine Although not studied, increased Contraindicated (see section [CYP3A4 substrates] plasma concentrations of 4.3) ivabradine can lead to QTc prolongation and rare occurrences of torsades de pointes. Mavacamten Although not studied, voriconazole Refer to the mavacamten [CYP2C19, CYP3A4 and is likely to increase the plasma summary of product CYP2C9 substrate] concentrations of mavacamten with characteristics (SmPC) for more increased risk of heart failure. information. Cystic fibrosis transmembrane conductance regulator potentiators Ivacaftor Although not studied, voriconazole Dose reduction of ivacaftor is [CYP3A4 substrate] is likely to increase the plasma recommended. concentrations of ivacaftor with risk of increased adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alprazolam (HOS-086171) mavacamten (HOS-109474) lead (HOS-085592) ivacaftor (HOS-109475) ivabradine (HOS-109426) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 7cc4a837ff3a25ae5dcbb2d1f1525086d542db6220d9ced57b82c1de87716f54 · Zeichen 20947–22424 im Abschnitt